Today: 7 February 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Applied Digital (APLD) Stock on December 5, 2025: AI Factory Boom, $16 Billion+ Leases and a New Debt Rating

Applied Digital (APLD) Stock on December 5, 2025: AI Factory Boom, $16 Billion+ Leases and a New Debt Rating

Date: December 5, 2025Ticker: NASDAQ: APLDDisclaimer: This article is for information and education only and is not financial advice. Key Takeaways 1. Where APLD Stock Stands on December 5, 2025 By late Friday, December 5, Applied Digital shares were trading around $30.56, down modestly on the day after hitting an intraday high of $35.90 and a low near $29.61. That kind of range in a single session tells you most of what you need to know about this name: volatility is not a bug, it’s the feature. Over longer horizons, the move is dramatic: MarketBeat’s recent trading recap pegs APLD’s
5 December 2025
··
Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025

Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025

Biomea Fusion, Inc. (NASDAQ: BMEA) is back in the spotlight after the company reported long‑term data showing that its experimental diabetes drug icovamenib (formerly BMF‑219) can deliver durable blood‑sugar control many months after patients stop taking it. The new results, presented at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles, pushed Biomea Fusion’s stock higher on Friday and have reignited debate over whether this beaten‑down biotech could still be a high‑risk turnaround story. Nasdaq+1 As of Friday, December 5, Biomea Fusion shares were trading in the low‑$1 range, giving the company a market
5 December 2025
··
Argan, Inc. (AGX) Stock Plunges After Record-Backlog Q3: What Today’s Selloff Means for Investors

Argan, Inc. (AGX) Stock Plunges After Record-Backlog Q3: What Today’s Selloff Means for Investors

Published: December 5, 2025 – All data as of U.S. morning trading on this date and subject to change. Key takeaways Argan stock today: from momentum favorite to double‑digit drop Coming into this week, Argan, Inc. was one of the hotter stories in construction and power infrastructure. Over the last 12 months, AGX is still up more than 100%, and earlier this week Zacks highlighted that shares were up nearly 18% in just one week before the latest earnings. TradingView+2ChartMill+2 Today is a different mood. After Thursday’s Q3 fiscal 2026 earnings release, AGX is trading around $302, down roughly 15%
5 December 2025
·
Rivian (RIVN) Stock Today: Recall News, AI Day Catalysts, and Fresh 2026–2030 Forecasts

Rivian (RIVN) Stock Today: Recall News, AI Day Catalysts, and Fresh 2026–2030 Forecasts

Rivian Automotive, Inc. (NASDAQ: RIVN) heads into the last month of 2025 as one of the most hotly debated EV stocks on the market. On Friday, December 5, 2025, Rivian shares are trading around $18.16, near a one‑year high after a powerful rally driven by better‑than‑expected Q3 results, a deepening software partnership with Volkswagen, and rising excitement about the company’s upcoming “Autonomy & AI Day” on December 11. Stock Invest At the same time, Rivian is dealing with a fresh recall of nearly 35,000 delivery vans and a wide gap between bullish growth narratives and more pessimistic valuation models. Here’s
5 December 2025
··
Gulf Resources (GURE) Stock Soars After Regaining Nasdaq Compliance: Q3 2025 Shock Losses, Reverse Split and 2026 Outlook

Gulf Resources (GURE) Stock Soars After Regaining Nasdaq Compliance: Q3 2025 Shock Losses, Reverse Split and 2026 Outlook

Gulf Resources, Inc. (NV) Common Stock (ticker: GURE) has suddenly jumped back onto traders’ radar in December 2025. The Chinese bromine and crude salt producer has regained compliance with Nasdaq’s listing requirements, executed a 1‑for‑10 reverse stock split, and seen its share price explode in early December trading — all against a backdrop of huge accounting losses and a formal going‑concern warning from management. Nasdaq+2NASDAQ Trader+2 This article brings together the latest news, earnings, technical signals and third‑party forecasts on Gulf Resources as of 5 December 2025, and explores what that means for GURE stock heading into 2026. Snapshot: What
5 December 2025
·
Comcast Stock (CMCSA) Rises as Versant Spin-Off Nears: Latest News, Analyst Targets, and 2026 Outlook

Comcast Stock (CMCSA) Rises as Versant Spin-Off Nears: Latest News, Analyst Targets, and 2026 Outlook

Comcast stock (CMCSA) is trading in the high‑$20s as the company moves ahead with its Versant Media Group spin‑off, digests mixed broadband trends, and faces sharply divided analyst opinions. Here’s the full picture as of December 5, 2025. Comcast stock on 5 December 2025: where things stand As of mid‑session on Friday, December 5, 2025, Comcast Corporation Class A shares (Nasdaq: CMCSA) were trading around $27.81, up roughly 2.2% on the day. The stock has moved off its recent 52‑week low near $25.75 but remains far below a one‑year high around $43.30. MarketBeat Over the past year, Comcast shares have
5 December 2025
··
Parsons Corporation (PSN) Stock Plunges After FAA Contract Loss: What December 5, 2025 Means for the Outlook

Parsons Corporation (PSN) Stock Plunges After FAA Contract Loss: What December 5, 2025 Means for the Outlook

Updated: December 5, 2025 Parsons Corporation (NYSE: PSN) is having one of its most volatile trading days since going public. After months of anticipation, the U.S. Federal Aviation Administration (FAA) chose rival Peraton—not Parsons—as the prime integrator for the massive “Brand New Air Traffic Control System” (BNATCS) overhaul. In late‑morning trading on Friday, December 5, 2025, Parsons stock was changing hands around $64 per share, down roughly 24% from Thursday’s close of $84.46, putting the name firmly among the day’s biggest decliners. StockAnalysis+1 Yet, on the same day, Parsons announced it had been selected for a $3.5 billion Defense Threat
5 December 2025
·
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) extended its remarkable 2025 rally on Friday, December 5, with shares surging almost 40% intraday after the company reported a double dose of good news: a pivotal epilepsy trial stopped early for efficacy and a positive pre-NDA meeting with the U.S. Food and Drug Administration (FDA) for its lead essential tremor drug. StockAnalysis+3TradingView+3Stock Titan+3 By late morning U.S. trading, PRAX was changing hands around $265–266, up roughly 40% on the day, with a market capitalization just over $1.1 billion, after hitting a new 52‑week high earlier in the session near $241. Investing.com+1 The stock
5 December 2025
MP Materials Stock (NYSE: MP): Morgan Stanley Upgrade, Saudi JV and a 41% Pullback – December 5, 2025 Update

MP Materials Stock (NYSE: MP): Morgan Stanley Upgrade, Saudi JV and a 41% Pullback – December 5, 2025 Update

MP Materials Corp (NYSE: MP) is closing out 2025 as one of the wildest rides in the S&P 500. After a year of government mega‑deals, geopolitical headlines and soaring rare‑earth prices, the stock now sits roughly 40% below its early‑year high but hundreds of percent above where it started the year. Simply Wall St+1 On December 5, 2025, the story added a fresh chapter: Morgan Stanley upgraded MP Materials to Overweight, a new batch of analyst targets landed in the $70–$80 range, and several in‑depth valuation pieces questioned whether the stock is now a strategic bargain or a speculative bubble.
5 December 2025
Sensei Biotherapeutics (SNSE) Stock: Wild Volatility After Solnerstotug Shutdown and Strategic Review – Price, News and 2025–2026 Forecast

Sensei Biotherapeutics (SNSE) Stock: Wild Volatility After Solnerstotug Shutdown and Strategic Review – Price, News and 2025–2026 Forecast

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) has suddenly landed back on traders’ radars. After months of drifting as a tiny, cash‑rich micro‑cap biotech, the stock exploded higher at the start of December 2025 – just weeks after the company killed its lead drug program and launched a strategic review. This article walks through the latest SNSE stock price moves, the full 2025 news timeline, the strategic review, analyst forecasts, and the key risks around this highly speculative name. It is informational only and not investment advice. SNSE stock price today: how high did Sensei Biotherapeutics jump? As of the regular session
5 December 2025
··
Akanda Corp (AKAN) Stock Soars After Shareholder Vote: Reverse Merger, Mexico Towers and 2025–2030 Forecasts

Akanda Corp (AKAN) Stock Soars After Shareholder Vote: Reverse Merger, Mexico Towers and 2025–2030 Forecasts

Published: December 5, 2025 Akanda Corp’s Nasdaq-listed shares (ticker: AKAN) are back in the spotlight after a dramatic late‑week move. On Thursday evening, the micro‑cap stock surged about 45% in after‑hours trading to roughly $1.37, after the company disclosed that shareholders had approved sweeping capital‑structure changes linked to its reverse merger with First Towers & Fiber Corp and a package of convertible debt. Benzinga+2Stock Titan+2 The spike caps a volatile stretch in 2025 during which Akanda has tried to reinvent itself from a tiny, loss‑making medical cannabis company into a hybrid telecom‑infrastructure and cannabis play with operations in Mexico and
5 December 2025
···
SciSparc (SPRC) Stock on December 5, 2025: Price Action, Quantum Data Deal, GERD Device Pivot and 2030 Forecast

SciSparc (SPRC) Stock on December 5, 2025: Price Action, Quantum Data Deal, GERD Device Pivot and 2030 Forecast

SciSparc Ltd. (NASDAQ: SPRC) is back on traders’ radar after a frenetic week of news that spans quantum bio‑data analytics, medical endoscopy devices and ongoing restructuring of its biotech portfolio. As of Friday, December 5, 2025, SciSparc shares are trading around $1.79–$1.80, after an early pre‑market jump of about 19% to $2.10, on volume that has already surged well above normal levels. StockAnalysis+1 Despite today’s bounce, the stock remains down roughly 60–75% over the past year and more than 95% below its 52‑week high of $37.59, leaving the company with a micro‑cap market value of roughly $5.6–$5.9 million. INDmoney+2Stock Titan+2
5 December 2025
··
Jeffs’ Brands (JFBR) Soars on Scanary AI Security Deal: Can the Rally Last?

Jeffs’ Brands (JFBR) Soars on Scanary AI Security Deal: Can the Rally Last?

Jeffs’ Brands Ltd (Nasdaq: JFBR) is back on traders’ radar on December 5, 2025, with the micro‑cap stock surging after the company announced a definitive distribution agreement for advanced AI security scanners with Israeli deep‑tech firm Scanary Ltd.GlobeNewswire+1 As of early afternoon U.S. trading, JFBR shares trade around $3.17, up roughly 27% from Thursday’s close of $2.50, after touching an intraday high of $4.21. Turnover has exploded to well over 20 million shares, dwarfing typical daily volumes in the low hundreds of thousands.TipRanks+1 Yet despite today’s rally, the stock remains a deeply battered micro‑cap: JFBR is still down more than
5 December 2025
·
NuScale Power (SMR) Stock on December 5, 2025: Rebound Rally, Share-Dilution Vote and a Split Wall Street

NuScale Power (SMR) Stock on December 5, 2025: Rebound Rally, Share-Dilution Vote and a Split Wall Street

Updated: December 5, 2025 NuScale Power Corporation (NYSE: SMR) has become one of the most hotly debated stocks in the nuclear and AI‑energy space. After a spectacular run‑up earlier in 2025 and a brutal sell‑off since mid‑October, the stock is now bouncing sharply again as investors weigh three big forces at once: As of mid‑day on December 5, 2025, NuScale shares trade around $22.85, up sharply from late‑November lows but still far below their October peak in the mid‑$50s. MarketBeat+1 Below is a detailed look at today’s news flow, the latest forecasts, and how analysts are trying to price this
5 December 2025
United States Antimony (UAMY) Stock in December 2025: Pentagon Deal, Mining Push and What Analysts Expect Next

United States Antimony (UAMY) Stock in December 2025: Pentagon Deal, Mining Push and What Analysts Expect Next

Updated: December 5, 2025 United States Antimony Corporation (NYSE American: UAMY) has quietly become one of the loudest tickers in the critical‑minerals trade of 2025. The micro‑cap producer, long overlooked, is now sitting at the intersection of U.S. defense policy, supply‑chain geopolitics and speculative trading. As of early trading on December 5, 2025, UAMY is hovering around $6–6.20 per share, after closing at $6.12 on December 4, a 15% jump on the day.StockInvest The stock has swung between $1.06 and $19.70 over the last 52 weeks, underlining just how volatile this new “critical minerals” play has become.StockInvest Behind the volatility
5 December 2025
···
SEALSQ Corp (LAES) Stock: Quantum-Security High‑Flier After EeroQ Deal – Outlook as of December 5, 2025

SEALSQ Corp (LAES) Stock: Quantum-Security High‑Flier After EeroQ Deal – Outlook as of December 5, 2025

As of December 5, 2025, SEALSQ Corp (NASDAQ: LAES) sits at the intersection of three crowded buzzwords—semiconductors, cybersecurity and quantum computing—and its stock has traded accordingly: violently. Shares are hovering in the mid‑$5 range after an 8%+ jump on December 4, capping a roughly 1,000% gain over the past year and a double‑digit rally over the last week.StockInvest+1 At the same time, the company remains unprofitable and richly valued, which makes SEALSQ one of the more speculative post‑quantum security plays in the market. This article summarizes the latest SEALSQ news, stock performance, forecasts and risks as of December 5, 2025.
5 December 2025
··
ASP Isotopes (NASDAQ: ASPI) Stock: CEO Comeback, HALEU Progress and 2026 Outlook

ASP Isotopes (NASDAQ: ASPI) Stock: CEO Comeback, HALEU Progress and 2026 Outlook

Updated December 5, 2025 – informational only, not investment advice. ASP Isotopes Stock Snapshot as of December 5, 2025 ASP Isotopes Inc. (NASDAQ: ASPI) continues to trade like a classic high‑risk, high‑story growth name. According to StockAnalysis, revenue over the last twelve months is only about $8–9 million, which implies a price‑to‑sales ratio above 50x and an EV/Sales ratio above 80x at recent prices – valuations that assume significant future growth. StockAnalysis+1 Analyst coverage is still thin: two analysts currently rate ASPI a “Strong Buy” with an average 12‑month price target of $12, implying potential upside of more than 80%
5 December 2025
·
Samsara (IOT) Stock Today: Q3 FY2026 Earnings Beat, First GAAP Profit and a Wave of New $50 Price Targets

Samsara (IOT) Stock Today: Q3 FY2026 Earnings Beat, First GAAP Profit and a Wave of New $50 Price Targets

As of December 5, 2025, Samsara Inc. (NYSE: IOT) has just delivered a landmark quarter: its first ever GAAP profit, another round of 29% top-line growth, and a fresh batch of Wall Street price targets clustered around $50 per share. Yet the stock is still trading in the low $40s and remains well below its 2025 peak, leaving investors debating whether IOT is a high‑growth bargain or a richly priced momentum story. Below is a detailed breakdown of the latest news, forecasts, and analyses around Samsara stock as of December 5, 2025. Samsara stock today: price, range and recent performance
5 December 2025
···
Inno Holdings (INHD) Stock Today: News, Forecasts and High‑Risk Opportunity in December 2025

Inno Holdings (INHD) Stock Today: News, Forecasts and High‑Risk Opportunity in December 2025

As of December 5, 2025, Inno Holdings Inc. (NASDAQ: INHD) has become one of the most volatile micro-cap names on the U.S. market, sitting near all‑time lows while simultaneously announcing ambitious growth plans and new tech partnerships. Inno Holdings (INHD) stock price and performance in December 2025 In midday trading on December 5, 2025, Inno Holdings Inc. stock is changing hands at around $0.14 per share on the Nasdaq Capital Market. That number doesn’t tell the full story. Over the past year, INHD has: This is classic micro‑cap “roller coaster” behavior: the company has a very small market capitalization of
5 December 2025
·
Hims & Hers Health (HIMS) Stock Today: Canada Expansion, Labs, GLP‑1 Growth and Fresh “Strong Buy” Call – Price, News & Forecast as of December 5, 2025

Hims & Hers Health (HIMS) Stock Today: Canada Expansion, Labs, GLP‑1 Growth and Fresh “Strong Buy” Call – Price, News & Forecast as of December 5, 2025

Hims & Hers Health, Inc. (NYSE: HIMS) is back in the market spotlight. As of early December 5, 2025, the telehealth company’s stock is trading around $40 per share, up sharply from recent lows but still far below its 52‑week high near $73.StockAnalysis In the last few weeks, Hims & Hers has: All of that is unfolding against a backdrop of regulatory scrutiny on GLP‑1 weight‑loss drugs, elevated short interest and a valuation that some see as stretched and others call undervalued. Below is a breakdown of where HIMS stock stands today, what the latest news means, and how Wall
5 December 2025
·
1 … 475 476 477 478 479 … 535

Stock Market Today

Costco stock price retakes $1,000 — what traders are watching before Monday

Costco stock price retakes $1,000 — what traders are watching before Monday

7 February 2026
Costco closed Friday up 1.2% at $1,001.16, regaining the $1,000 level as about 2.36 million shares changed hands. January net sales rose 9.3% to $21.33 billion, with comparable sales up 7.1% and online sales surging 34.4%. Wells Fargo raised its price target to $950, maintaining a neutral rating. The next earnings call is set for March 5.
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

7 February 2026
Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
Go toTop